trending Market Intelligence /marketintelligence/en/news-insights/trending/tH0WPzG625i-8R_3GxVvbQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Kazia to sell remaining stake in Noxopharm for A$2.1M

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Kazia to sell remaining stake in Noxopharm for A$2.1M

Kazia Therapeutics Ltd. is selling its remaining stake in Noxopharm Ltd. through a single block trade for proceeds of about A$2.1 million.

The Sydney-based biotechnology company, which develops therapies for cancer, plans to use the proceeds for research and development.

Kazia, formerly known as Novogen, retains 3 million unlisted options in Noxopharm, which are exercisable at 80 cents each.

Kazia and Australia-based Noxopharm entered a collaboration in 2017 to develop the latter's cancer therapy NOX66. In return, Kazia agreed to take a small equity interest in Noxopharm.

The sale brings the total gross proceeds of Kazia's sale of its holding in Noxopharm to about A$2.4 million.